Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Operational Highlights
VTRS logo

Viatris Faces $2.94B Goodwill Impairment Amid 11% Sales Drop

VTRS10-QFiling Date: 5/8/2025
Viatris Inc.
Description

What this story covers

Viatris reported Q1 2025 revenues down 11% to $3.25B due to divestitures and Indore FDA alert costing $140M. Net loss of $3.04B driven by $2.94B goodwill impairment. Cash flow positive at $536M; strategic acquisitions like Idorsia assets and share repurchases signal focus on innovation and shareholder returns. Liquidity robust despite risks from tariffs and litigation.

Story snapshot

CompanyViatris Inc.
TickerVTRS
VariantStandard detailed
Duration13:06
Filing type10-Q
PeriodQ1 2025
IndustryHealthcare & Pharmaceuticals
Accession0001792044-25-000018

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in